XML 33 R23.htm IDEA: XBRL DOCUMENT
v3.8.0.1

9. Stock Compensation (Dec. 2017 Note) | 9 Months Ended
--- | ---
Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |
Stock Compensation | The following tables summarize share-based compensation expenses relating to Restricted Stock Units (“RSU”s) and options granted and the effect on basic and diluted loss per common share during the three and nine month periods ended December 31, 2017 and 2016:
|  | Three Months Ended December 31, 2017 |  |  | Three Months Ended December 31, 2016 |  |  | Nine Months Ended December 31, 2017 |  |  | Nine Months Ended December 31, 2016 |
Vesting of stock options and restricted stock units |  | $ | 323,162 |  |  | $ | 306,159 |  |  | $ | 887,607 |  |  | $ | 1,880,150 |
Total stock-based compensation expense |  | $ | 323,162 |  |  | $ | 306,159 |  |  | $ | 887,607 |  |  | $ | 1,880,150 |
Weighted average number of common shares outstanding – basic and diluted |  |  | 14,950,701 |  |  |  | 7,927,031 |  |  |  | 10,927,106 |  |  |  | 7,768,682 |
Basic and diluted loss per common share attributable to stock-based compensation expense |  | $ | (0.02 | ) |  | $ | (0.04 | ) |  | $ | (0.08 | ) |  | $ | (0.24 | )
All of the stock-based compensation expense recorded during the nine months ended December 31, 2017 and 2016, which totaled $887,607 and $1,880,150, respectively, is included in payroll and related expense in the accompanying condensed consolidated statements of operations. Stock-based compensation expense recorded during the nine months ended December 31, 2017 and 2016 represented an impact on basic and diluted loss per common share of $(0.08) and $(0.24), respectively. We review share-based compensation on a quarterly basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeiture adjustments for the nine months ended December 31, 2017 was insignificant. Restricted Stock Unit Grants to Directors and Executive Officers On August 9, 2016, our Board of Directors granted RSUs to certain of our officers and directors and effective November 7, 2017, 127,659 additional RSUs were granted to our directors pursuant to the 2012 Non-Employee Directors Compensation Program. The RSUs represent the right to be issued on a future date shares of our common stock for vested RSUs. Our Compensation Committee recommended the grants based on a compensation assessment provided by a third-party compensation consulting firm engaged by us that developed a peer group of companies for market assessment and analyzed compensation at such companies. The RSUs were granted under our Amended 2010 Stock Incentive Plan and we recorded expense of $842,095 in the nine months ended December 31, 2017 related to the RSU grants. RSUs outstanding that have vested and are expected to vest as of December 31, 2017 are as follows:
|  | Number of RSUs |
Vested |  |  | 46,125 |
Expected to vest |  |  | 432,830 |
Total |  |  | 478,955 |
During the nine months ended December 31, 2017, 138,375 vested RSUs held by our executives were exchanged into the same number of shares of our common stock. As our executives elected to net settle a portion of their RSU’s in exchange for the Company paying the related withholding taxes on the share issuance, 71,081 of the RSUs were cancelled and we issued a net 67,294 shares to our executives. During the nine months ended December 31, 2017, 63,829 RSUs held by our outside directors were exchanged into the same number of shares of our common stock. As one of our three outside directors elected to return 40% of his RSUs in exchange for cash in order to pay his withholding taxes on the share issuances, 10,638 of the RSUs were cancelled and we paid $12,127 in cash to that outside director. Stock Option Activity During the nine months ended December 31, 2017, we issued options to four of our employees to purchase 34,500 shares of common stock at a price of $1.68 per share, the closing price on the date of the approval of the option grants by our compensation committee. There were no stock option grants during the nine months ended December 31, 2016. Options outstanding that have vested and are expected to vest as of December 31, 2017 are as follows:
|  | Number of Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term in Years |
Vested |  |  | 432,047 |  |  | $ | 10.98 |  |  |  | 3.64 |
Expected to vest |  |  | 27,000 |  |  | $ | 1.68 |  |  |  | 9.46 |
Total |  |  | 459,047 |  |  |  |  |  |  |  |  |
The following outlines the significant weighted average assumptions used to estimate the fair value information presented, with respect to stock option grants utilizing the Binomial Lattice option pricing models at, and during the nine months ended December 31, 2017:
Risk free interest rate |  |  | 2.21% |
Average expected life |  |  | 10 years |
Expected volatility |  |  | 92.14% |
Expected dividends |  |  | None |
The expected volatility was based on the historic volatility. The expected life of options granted was based on the "simplified method" as described in the SEC's guidance due to changes in the vesting terms and contractual life of current option grants compared to our historical grants. A summary of stock option activity during the nine months ended December 31, 2017 is presented below:
|  | Amount |  |  | Range of Exercise Price |  |  | Weighted Average Exercise Price |
Stock options outstanding at March 31, 2017 |  |  | 432,047 |  |  |  | $3.80-$20.50 |  |  |  | $10.98 |
Exercised |  |  | – |  |  |  | – |  |  |  | – |
Granted |  |  | 27,000 |  |  |  | $1.68 |  |  |  | $1.68 |
Cancelled/Expired |  |  | – |  |  |  | – |  |  |  | – |
Stock options outstanding at December 31, 2017 |  |  | 459,047 |  |  |  | $1.68-$20.50 |  |  |  | $10.44 |
Stock options exercisable at December 31, 2017 |  |  | 432,047 |  |  |  | $3.80-$20.50 |  |  |  | $10.98 |
On December 31, 2017, our stock options had no intrinsic value since the closing price on that date of $1.13 per share was below the weighted average exercise price of our stock options. At December 31, 2017, there was approximately $2.2 million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of 1.72 years.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration